Robert Polk
Psychiatric/Mental Health · Houston, TXNPI 1982287314
Payments from drug & device makers
Across 324 payments — averaging $22.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$960
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$916
- AbbVie$908
- Neurocrine Biosciences, Inc.$627
- Otsuka America Pharmaceutical, Inc.$574
- Axsome Therapeutics, Inc.$393
- plus $3K from 21 others
What the payments were for
- Food & beverage$7,11899%
- Education$1061%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 38 | $960 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 35 | $916 |
| AbbVie | 53 | $908 |
| Neurocrine Biosciences, Inc. | 22 | $627 |
| Otsuka America Pharmaceutical, Inc. | 30 | $574 |
| Axsome Therapeutics, Inc. | 19 | $393 |
| Alkermes, Inc. | 12 | $390 |
| Ironshore Pharmaceuticals Inc. | 13 | $264 |
| Corium, LLC | 10 | $237 |
| Idorsia Pharmaceuticals US Inc | 12 | $229 |
| Tris Pharma Inc | 15 | $218 |
| Vanda Pharmaceuticals Inc. | 11 | $207 |
| E.r. Squibb & Sons, L.L.C. | 6 | $199 |
| Johnson & Johnson | 6 | $196 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $167 |
| Merck | 7 | $118 |
| Phathom Pharmaceuticals, Inc. | 1 | $106 |
| Lundbeck LLC | 6 | $105 |
| Almatica Pharma LLC | 6 | $105 |
| Neos Therapeutics, LP | 4 | $70 |
| Indivior Inc. | 3 | $60 |
| Amgen | 1 | $48 |
| Antares Pharma, Inc. | 1 | $42 |
| Livanova USA, Inc. | 1 | $27 |
| Noven Therapeutics, LLC | 1 | $22 |
| Biogen | 1 | $22 |
| Noven Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$449
- ARISTADA$415
- CAPLYTA$231
- VOQUEZNA$106
- VRAYLAR$104
- ARISTADA INITIO$104
- COBENFY$102
- Austedo XR$100
How this compares
$7,224 in reported general payments places this provider in the 90th percentile of 2,724 psychiatric/mental health providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 15 | $204,961 |
| IngrezzaValbenazine Tosylate | 12 | $106,830 |
| VraylarCariprazine Hcl | 49 | $72,723 |
| RexultiBrexpiprazole | 21 | $31,971 |
| LatudaLurasidone Hcl | 11 | $14,828 |
| AuvelityDextromethorphan Hbr/Bupropion | 12 | $12,186 |
| Lurasidone Hcl | 25 | $7,590 |
| Aripiprazole | 137 | $6,335 |
| Quetiapine Fumarate | 240 | $3,229 |
| Sertraline Hcl | 417 | $2,955 |
| Duloxetine Hcl | 131 | $2,211 |
| Bupropion XlBupropion Hcl | 201 | $2,164 |
| Trazodone Hcl | 282 | $2,086 |
| Buspirone Hcl | 223 | $2,073 |
| Hydroxyzine Hcl | 148 | $1,552 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $960 | $204,96115 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $627 | $106,83012 claims |
| AbbVieVraylar | $908 | $72,72349 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $574 | $31,97121 claims |
| Axsome Therapeutics, Inc.Auvelity | $393 | $12,18612 claims |
| Almatica Pharma LLCSertraline Hcl | $105 | $2,955417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 psychiatric/mental health providers in Texas.
Other psychiatric/mental health in Houston
- Natalie TellezHouston$602K
- Britney PridgenHouston$57K
- Linzi LeightonHouston$16K
- Samantha SharpeHouston$14K
- Jennifer RobinsonHouston$12K
- Tracy HicksLongview$684K
- Karah BrashierRichardson$567K
- Grant DavisRichardson$360K
- Victor IlogEl Paso$167K
- Lisa ShamblinGrapevine$163K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.